Background: The aim of this study was to investigate the clinicopathological characteristics of GATA binding protein 3 (GATA3)-positive breast cancers as well as the association of GATA3 expression with response to chemotherapy.
introduction GATA binding protein 3 (GATA3) belongs to the GATA family, which consists of six GATA transcription factors (GATA1-6) that bind to the consensus (A/T)GATA(A/G) motif [1] . GATA3 is a 444-amino-acid transcription factor located in 10p15 and possesses an activation domain (exons 2 and 3) and a DNA binding domain (exons 4 and 5) [2] . GATA3 was initially identified as a DNA-binding protein involved in the activation of transcription at the T-cell receptor alpha locus and has been shown to be implicated in the development of T-cells. Later studies have revealed that GATA3 is also involved in the development of various organs including the mammary gland [1] .
GATA3 is critical for the normal development of the mammary gland. Introduction of GATA3 into a purified mammary progenitor-enriched population has been shown to induce luminal cell differentiation [3] . In human breast tissue, GATA3 is expressed in the luminal epithelial cells, and its expression is also seen in breast cancer [4, 5] . The expression of GATA3 is closely associated with estrogen receptor (ER) and forkhead box A1 (FOXA1) expression in breast cancer [4, 6] . FOXA1 plays an important role in the transcriptional function of ER [7] . It has also been suggested that GATA3 may be a mediator for the transcriptional up-regulation of mucin 1 (MUC1) in breast cancer [8] . These results clearly indicate that GATA3 plays a pivotal role in the development and differentiation of luminal epithelial cells, which is consistent with the preferential expression of GATA3 in luminal-type breast cancer [9] . Somatic mutations of GATA3 are reported to occur infrequently (4%-5%) in breast tumors. Interestingly, these mutations are mostly seen in ER-positive tumors, suggesting involvement of GATA3 mutation in the pathogenesis of luminal-type breast cancer [10, 11] .
Because of this crucial function of GATA3, GATA3-positive tumors are thought to be derived from luminal progenitors and to maintain the luminal epithelial cell phenotype. In fact, GATA3-positive tumors are often ER-positive tumors, and a large body of studies has demonstrated that GATA3 expression is significantly associated with a favorable prognosis, suggesting that GATA3 may serve as a new prognostic factor for breast cancer [12] . On the other hand, the relationship of GATA3 expression with response to chemotherapy has rarely been studied. Since GATA3 expression is associated with ER expression, which has been shown to be associated with a poor response to chemotherapy [13] , it is speculated that GATA3 expression is also associated with a poor response. Moreover, since GATA3 induces a variety of luminal epithelial cell-related genes including ER, GATA3 may be even more strongly associated with resistance to chemotherapy. In the study presented here, we therefore tried first to elucidate the clinicopathological characteristics of GATA3-positive tumors and, next, to investigate the association of GATA3 expression with response to neoadjuvant chemotherapy for breast cancer. In addition, we studied whether or not GATA3 and FOXA1 could cooperate to induce ER in human breast cancer tissues since FOXA1, like GATA-3, has been reported to induce ER [6, 7] , and also studied the correlation of MUC1 with response to neoadjuvant chemotherapy since MUC1 is induced by GATA3 [8] and is shown to be implicated in resistance to chemotherapy [14] . 
patients and methods

immunohistological examination
Paraffin sections (2 μm) were subjected to immunohistochemistry for GATA3, FOXA1, and MUC1. The sections for GATA3 were deparaffinized and incubated with HistoVT one® ( pH7.0, citrate buffer; Nacalai Tesque Inc., Kyoto, Japan) for 40 min at 98°C, those for FOXA1 were incubated with Target Retrieval Solution® ( pH6.0, citrate buffer; DAKO Japan Inc., Tokyo, Japan) for 20 min at 98°C, and those for MUC1 were incubated with Target Retrieval Solution® ( pH6.0, citrate buffer; DAKO Japan Inc.) for 40 min at 98°C. These sections were then incubated with anti-GATA3 antibodies (HG3-31 mouse monoclonal antibody, 1/100; Santa Cruz Biotechnology Inc., Santa Cruz, CA), anti-FOXA1 antibodies (Q6 mouse monoclonal antibody, 1/1000; Santa Cruz Biotechnology), or anti-MUC1 antibodies (DF3 mouse monoclonal antibody, 1/100; Abcam Inc., Tokyo, Japan) for 1 h at room temperature, followed by incubation with the secondary antibody (Biotin Anti Mouse IgG, 0.33 mg/ml; Jackson Immunoresearch, West Grove, PA) for 1 h at room temperature, and subsequent treatment with the avidin-biotinylated peroxidase complex method for visualization. Positive and negative controls were used for each run [15] [16] [17] . Percentages of immunohistochemically positive tumor cells were determined by counting 1000 tumor cells with WinROOF® (Mitani Corp., Fukui, Japan). Immunohistochemical findings for GATA3 and FOXA1 were considered positive when the percentage of positive tumor cells (nuclear staining) was >10% and >40%, respectively. MUC1 was considered positive when the percentage of positive tumor cells (membranous staining) was >10%. These cut-off values for GATA3, FOXA1, and MUC1 were decided so that P value for their correlation with pathological complete response ( pCR) became minimal. Immunohistochemical assessments of ER, progesterone receptor (PgR), and Ki67 and FISH of human epidermal growth factor receptor 2 (HER2) in tumor biopsy samples were carried out as previously described [18] .
evaluation of response to chemotherapy
Pathological response to P-FEC was evaluated by examining the surgical specimens obtained at surgery. The specimens were cut into 5-mm sections, which were hematoxylin and eosin stained for the presence or absence of tumor cells. A complete loss of invasive tumor cells in the primary tumor site without any lymph node metastasis was classified as pCR.
sequence analysis of GATA3
DNA was extracted with the DNeasy Blood & Tissue Kit® (Qiagen, Tokyo, Japan) from tumor biopsy samples and subjected to mutational analysis for detection of exons 4, 5, and 6 of GATA3 by direct sequencing [19] . The primer sequences and PCR conditions are shown in Supplemental Table S1 (available at Annals of Oncology online).
intrinsic subtyping RNA was extracted with Trizol® Reagent (Life Technologies Inc., Gaithersburg, MD) from the tumor biopsy samples and subjected to gene expression analysis using U133 Plus 2.0 array® (Affymetrix, Santa Clara, CA) and intrinsic subtyping (luminal A, luminal B, HER2 enriched, basal like, normal breast like) according to a previously described method [20] .
statistics Dr. SPSS II (11.0.1J; SPSS Japan Inc., Tokyo, Japan) was used for all statistical analyses. Associations between the various clinicopathological parameters and GATA3 expression were assessed by means of the chisquared test or Fisher's exact test. Associations of the various clinicopathological parameters with pCR were evaluated by using uni-and multivariate analysis (logistic regression analysis). Hierarchal cluster analysis was carried out according to the method specified for Genomics Suite 6.5 (version 6.11.0321; Partek Inc., St Louis, MI). Statistical analysis was two-sided and P < 0.05 was considered to be significant except for selection of the genes differentially expressed in GATA3-positive and GATA3-negative tumors by means of the Welch t-test, where P < 9.15 × 10 −7 was considered to be significant after Bonferroni correction. (Figure 2 ). Since the number of normal breast-like tumors was so small and since it is suggested that normal breast-like might result from the contamination by the normal breast tissue [21] , normal breast-like tumors were not considered in the following analysis. Frequency of GATA3-positive tumors was significantly higher for luminal A than luminal B tumors (P = 0.001), HER2-enriched tumors (P < 0.001), and basal-like tumors (P < 0.001) ( Table 2) .
associations of GATA3 and FOXA1 with ER expression
Tumor tissues of 123 patients could be used for simultaneous analysis of GATA3, FOXA1, and ER. Representative results of FOXA1 are shown in Figure 1 . Of the 71 GATA3-positive tumors, 52 were positive for FOXA1, and of the 52 GATA3-negative tumors, 36 were negative for FOXA1. There was a significant (P < 0.001) association between GATA3 and FOXA1 expression. 
mutation analysis of GATA3
DNA from 99 tumors could be used for mutational analysis. Three somatic mutations, including one missense mutation (1754 G>A), one insert mutation (1873 CCC insert) and one deletion mutation (1888-1902 deletion), were identified (mutation rate, 3%). All three tumors which have somatic mutation were GATA3-positive, ER-positive tumors, and were classified as luminal A (n = 2) or luminal B (n = 1) tumors following intrinsic subtyping. Besides, pCR was not observed in any of them.
GATA3 for prediction of pathological response
pCR was observed in 8 (11%) of 74 GATA3-positive tumors and in 22 (39%) of 56 GATA3-negative tumors (P < 0.001) (Supplemental Figure S1 , available at Annals of Oncology online). Univariate analysis of clinicopathological parameters showed that tumor size (P = 0.01), ER (P < 0.001), PgR (P = 0.004), HER2 (P = 0.004), Ki67 (P = 0.027), and GATA3 (P < 0.001), but not FOXA1 and MUC1, were significantly associated with pCR rate (Table 3) . Multivariate analysis identified tumor size (P = 0.037), HER2 (P = 0.027), and GATA3 (P = 0.036) as independent predictors of pCR rate (Table 3) .
differentially expressed genes in GATA3-positive and GATA3-negative tumors
The 37 genes, corresponding to the 57 probes and differentially expressed in GATA3-positive and GATA-negative tumors, were selected by using the P value (9.15 × 10
) determined after Bonferroni correction. The list of these differentially expressed genes with annotations is shown in Supplemental Table S3 (available at Annals of Oncology online). Of the 57 probes, 21 (37%) were related to metabolism, 9 (16%) to gene transcription, 6 (11%) to signal transduction, 5 (9%) to mucin secretion, 2 (4%) to proliferation, 2 (4%) to DNA repair, and 12 (21%) were unknown.
discussion
For current study, we first studied the associations between GATA3 expression and the various conventional clinicopathological parameters in order to elucidate the characteristics of GATA3-positive tumors. Immunohistochemical examination showed that such tumors were more likely to be ER-positive and PgR-positive tumors and were more likely to be luminal A tumors as determined by gene expression profiling. These findings are consistent with the function of GATA3 in which it plays a pivotal role in differentiation into luminal epithelial cells. Similar results for the preferential expression of GATA3 in luminal A tumors have also been reported by Chou et al. [22] . Interestingly, we found that all infiltrating lobular cancers were GATA3-positive as was also found by Albergaria et al. [23] . It has been reported that GATA3 expression is relatively high in the terminal end buds from which lobular carcinomas are thought to stem, so that infiltrating lobular cancers are considered to be breast tumors, which have highly differentiated into luminal cells. In fact, all infiltrating lobular cancers in our study were classified as luminal A tumors.
Since GATA3 and FOXA1 have been reported to induce ER synergistically in in vitro studies [22, 24, 25] , we investigated whether such a cooperation can also be observed in human breast cancers. We found that both GATA3-and FOXA1-positive tumors showed the highest ER positivity and that both GATA3-and FOXA1-negative tumors showed the lowest positivity, while either GATA3-or FOXA1-positive tumors showed intermediate positivity. These results seem to be consistent with the in vitro findings that GATA3 and FOXA1 cooperate to induce ER in breast cancer.
It has been reported that 4%-5% of breast cancers harbor somatic mutations of GATA3, which are predominantly located in exons 4-6 [10, 11] . Consistent with this finding, we , luminal B, HER2 enriched, basal-like, and normal breast like) was done by DNA microarray analysis of gene expression with a previously described method [20] . Hierarchal cluster analysis was done in each subtype and the results are shown as a heatmap. The genes used for classification is also shown in the Supplementary Table 2 (available at Annals of Oncology online). Bars at the bottom show the immunohistochemical results for ER, PR, HER2, Ki67, GATA3, and FOXA1 as well as the pathological response. ER, estrogen receptor; FOXA1, forkhead box A1; GATA3, GATA binding protein 3; HER2, human epidermal growth factor receptor 2; OR, odds ratio; pCR, pathological complete response; PR, progesterone receptor. 
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tumors (5%) were found to harbor somatic mutations and all these tumors were ER positive [10] . Since GATA3 causes invasive breast cancer cells to undergo reversal of epithelialmesenchymal transition, leading to the suppression of cancer metastasis [26] , and it regulates tumor differentiation and suppresses tumor dissemination in breast cancer [5] , GATA3 is thought to have a tumor suppressive effect. Putting these results together leads to the speculation that loss of GATA3 function is implicated in the pathogenesis of luminal-type breast cancer even though its incidence is very low (< 5%). It is well known that ER positivity is associated with a poor response to chemotherapy, and, indeed, we found in this study that the pCR rate of ER-positive tumors (12%) was significantly lower than that of ER-negative tumors (40%). The precise reason for this association still remains to be investigated but one hypothesis is that ER serves as a marker of luminal epithelial differentiation and that well-differentiated tumors are generally thought to be less likely to respond to chemotherapy than less differentiated tumors. We next examined the relationship between GATA3 expression and pCR rate because GATA3 is a master gene for luminal differentiation and can thus be expected to reflect the luminal differentiation status more accurately than ER expression and may serve as a better marker of resistance to chemotherapy than ER. We were able to demonstrate that GATA3-positive tumors were significantly less likely to achieve pCR, and multivariate analysis results showed that GATA3 positivity was significantly associated with a lower pCR rate as well as that this association was independent of other clinicopathological parameters including ER. To the best of our knowledge, ours is the first report to demonstrate that GATA3 is a better predictor than ER of response to chemotherapy.
Since GATA3 induces a variety of genes during luminal differentiation, we speculated that some of these might play a significant role in the resistance to chemotherapy. We therefore investigated the genes differentially expressed in GATA3-positive and GATA3-negative tumors and were able to identify 37 genes implicated in apoptosis, DNA repair, cell cycle regulation, and metastasis (Supplemental Table S3 , available at Annals of Oncology online). The inclusion of trefoil factor 1 (TFF1) in these genes was noteworthy since it was significantly highly expressed in GATA3-positive tumors and is known to inhibit the cytochrome C-or Fas-induced activation of caspase 8 [27] . This suggests that TFF1 may play a significant role in the resistance to chemotherapy through the inhibition of apoptosis. It has also been suggested that phosphoserine aminotransferase 1 (PSAT1) is implicated in chemoresistance by decreasing the apoptotic response in colon cancer cell [28] . Moreover, anterior gradient 2 homolog (AGR2) is reportedly implicated in resistance to gemcitabine in pancreatic cancer cell lines [29] and cyclin D1 (CCND1) is also reported to play a significant role in resistance to docetaxel in in vitro [30] . In addition, high expression of CCND1 in GATA3-positive tumors is compatible with the recent finding that CCND1 is a direct transcriptional target of GATA3 in neuroblastoma tumor cells [31] . However, the precise mechanism of the resistance of GATA3-positive tumors to chemotherapy still needs to be investigated.
A limitation of this study is that the GATA3 cut-off value was decided so that the P value for the correlation between GATA3 and pathological response would become minimal, implying that this could be a hypothesis-raising study and thus the predictive value of GATA3 is overrated. Our present observation needs to be validated in future. However, the fact that the median value of GATA3 was also 10% seems to indicate that the association of GATA3 expression with resistance to chemotherapy may be plausible since dichotomization using a median value is a less biased method.
In conclusion, our results showed that GATA3-positive tumors possessed a phenotype of luminal A tumors and GATA3 mutations were found in only 3% of breast tumors. Furthermore, GATA3 was found to be an independent predictor of response to chemotherapy for human breast cancer, suggesting that GATA3 may be clinically useful as a references
